DelveInsight’s, “COVID-19 Pipeline Insight 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in COVID-19 pipeline landscape. It covers the COVID-19 pipeline drug profiles, including clinical and nonclinical stage products. It also covers the COVID-19 therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the COVID-19 Pipeline. Dive into DelveInsight’s comprehensive report today! @ COVID-19 Pipeline Outlook

Key Takeaways from the COVID-19 Pipeline Report

• Nov. 26, 2025 — A new study has uncovered distinct trajectories of long COVID, offering deeper insight into how the condition progresses over time. Published online on Nov. 17 in Nature Communications, the research was led by Tanayott Thaweethai, Ph.D., of Massachusetts General Hospital Biostatistics in Boston. The team analyzed data from 3,659 participants enrolled in the National Institutes of Health’s RECOVER Adult Cohort, tracking their long COVID symptoms using a specialized research index measured between three and 15 months post-infection. The findings reveal clear longitudinal patterns, marking an important step toward understanding patient recovery timelines and supporting future therapeutic development.
• On 18 November 2025, Pfizer announced a study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible participants will be randomly assigned (by chance) to receive ibuzatrelvir or matching placebo orally for 5 days. Co-administration of locally available standard of care is allowed. The total duration of the study is around 6 months.
• DelveInsight’s COVID-19 Pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for COVID-19 treatment.
• The leading COVID-19 Companies such as Ansun Pharm, Biophytis, MetrioPharm, GeneOne Life Science, Shionogi, Sinocelltech, Laurent Pharmaceuticals, Frontier Biotechnologies, Eyegene, aptaTargets, Veru Inc., Corvus Pharmaceuticals, Revive Therapeutics, Regeneron Pharmaceuticals, Hoffmann-La Roche, CytoDyn, Incyte Corporation/Novartis, SAB Biotherapeutics, Moderna Therapeutics, Pfizer, FibroGen, Arch Biopartners, Senhwa Biosciences, Ionis Pharmaceuticals, GlycoMimetics, Akari Therapeutics, Serpin Pharma and others.
• Promising COVID-19 Pipeline Therapies such as Calcium Dobesilate, Mannitol, Interferon-Alpha2B, WPV01, ILT101, Ibuzatrelvir, Remdesivir, and others.

Get insights into COVID-19 clinical trials, emerging therapies, and leading companies with DelveInsight @ COVID-19 Treatment Drugs

The COVID-19 Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The COVID-19 Pipeline Report also highlights the unmet needs with respect to the COVID-19.

COVID-19 Overview

Coronavirus disease (COVID-19) is an infectious disease caused by the most recently discovered corona virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease causes respiratory illness (like the flu) with symptoms such as a cough, fever, and difficulty breathing. Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness and recover without requiring special treatment. Elderly people and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer are more likely to develop serious illness. The COVID-19 virus is primarily transmitted through droplets of saliva or discharge from the nose when an infected person coughs or sneezes.

COVID-19 Emerging Drugs Profile

• DAS181: Ansun Pharm

DAS181 is a recombinant sialidase enzyme that works by removing sialic acids from the lung surface so that influenza cannot bind to infect. This interrupts the virus lifecycle and allows patients the chance to recover. By targeting the host rather than the virus, DAS181 is less susceptible to drug resistant strains of virus, and by targeting the host rather than a specific virus, DAS181 works for other viruses that use sialic acid receptors. DAS181 is delivered in a nebulized formulation using Aerogen Solo aerosol drug delivery technology. The U.S. Food and Drug Administration (FDA) has granted both Fast Track and Breakthrough Therapy Designation to DAS181. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Covid-19.

• Sarconeos (BIO101): Biophytis

Sarconeos (BIO101) is an orally administered small molecule in development for the treatment of neuromuscular diseases. Based on results from cellular and animal studies, it is believed that Sarconeos (BIO101) stimulates biological resilience through activation of the MAS receptor and may have the potential to improve muscle function and preserve strength, mobility and respiratory capacity in various age-related and muscular wasting conditions. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Covid-19.

• MP1032: MetrioPharm

MP1032 is a unique small molecule targeting overshooting reactions of activated immune cells by addressing a central, natural metabolic process occurring in activated immune cells. The mitochondria of these cells react to the activation by boosting their energy metabolism, which in turn leads to the generation of reactive oxygen species (ROS) and an increase of intercellular pH. MP1032 is activated only by clusters of elevated pH and acts as an ROS scavenger, normalizing the pathologically increased ROS levels (oxidative stress). Once the pH returns to normal, the drug stops is no longer activated and working. This unique, self-regulating mechanism of action makes MP1032 a first-in-class anti-inflammatory drug that reduces excessive ROS without interfering with the physiological ROS levels of other cells that are essential for normal cell function, resulting in an excellent safety profile. Currently, the drug is in Phase II stage of its development for the treatment of Covid-19.

• GLS-5310: GeneOne Life Science

GLS-5310 is a DNA vaccine encoding the spike (S) protein and a second antigenic target of SARS-CoV-2. StateGLS-5310 is being developed with support from the Government of Korea, through the Centers for Disease Control and Prevention, as part of a national project to develop COVID-19 vaccines. GLS-5310 is in pre-clinical development. Currently, the drug is in Phase I/II stage of its development for the treatment of Covid-19.

• S-892216: Shionogi

S-892216, developed by Sumitomo Pharma, is being investigated for its potential in treating COVID-19-related acute respiratory distress syndrome (ARDS). Acting as a serotonin 5-HT2A receptor agonist, it aims to regulate immune responses and mitigate excessive inflammation associated with severe COVID-19. The compound represents a novel approach to addressing cytokine storms and improving outcomes in critically ill patients. Currently the drug is in Phase I stage of its clinical development for the treatment of Covid-19.

Explore groundbreaking therapies and clinical trials in the COVID-19 Pipeline. Access DelveInsight’s detailed report now! @ New COVID-19 Drugs

The COVID-19 Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of COVID-19 with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for COVID-19 Treatment.
• COVID-19 Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• COVID-19 Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the COVID-19 market

COVID-19 Companies

Ansun Pharm, Biophytis, MetrioPharm, GeneOne Life Science, Shionogi, Sinocelltech, Laurent Pharmaceuticals, Frontier Biotechnologies, Eyegene, aptaTargets, Veru Inc., Corvus Pharmaceuticals, Revive Therapeutics, Regeneron Pharmaceuticals, Hoffmann-La Roche, CytoDyn, Incyte Corporation/Novartis, SAB Biotherapeutics, Moderna Therapeutics, Pfizer, FibroGen, Arch Biopartners, Senhwa Biosciences, Ionis Pharmaceuticals, GlycoMimetics, Akari Therapeutics, Serpin Pharma and others.

COVID-19 pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

COVID-19 Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Learn about new COVID-19 drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ COVID-19 Market Drivers and Barriers

Scope of the COVID-19 Pipeline Report

• Coverage- Global
• COVID-19 Companies- Ansun Pharm, Biophytis, MetrioPharm, GeneOne Life Science, Shionogi, Sinocelltech, Laurent Pharmaceuticals, Frontier Biotechnologies, Eyegene, aptaTargets, Veru Inc., Corvus Pharmaceuticals, Revive Therapeutics, Regeneron Pharmaceuticals, Hoffmann-La Roche, CytoDyn, Incyte Corporation/Novartis, SAB Biotherapeutics, Moderna Therapeutics, Pfizer, FibroGen, Arch Biopartners, Senhwa Biosciences, Ionis Pharmaceuticals, GlycoMimetics, Akari Therapeutics, Serpin Pharma and others.
• COVID-19 Pipeline Therapies such as Calcium Dobesilate, Mannitol, Interferon-Alpha2B, WPV01, ILT101, Ibuzatrelvir, Remdesivir, and others.
• COVID-19 Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• COVID-19 Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight’s in-depth pipeline report today! @ COVID-19 Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. COVID-19: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. DAS181: Ansun Pharm
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. MP1032: MetrioPharm
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I/II)
13. GLS-5310: GeneOne Life Science
14. Drug profiles in the detailed report…..
15. Preclinical and Discovery Stage Products
16. Drug Name: Company Name
17. Drug profiles in the detailed report…..
18. Inactive Products
19. COVID-19 Key Companies
20. COVID-19 Key Products
21. COVID-19- Unmet Needs
22. COVID-19- Market Drivers and Barriers
23. COVID-19- Future Perspectives and Conclusion
24. COVID-19 Analyst Views
25. COVID-19 Key Companies
26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/covid-19-pipeline-insight